Sodium Phenylbutyrate Market 2026: Primary Research + Expert Analysis

Sodium Phenylbutyrate by Application (Hospital, Clinic, Other), by Types (Tablets, Granules, Powder), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sodium Phenylbutyrate Market Size | CAGR 7.5 Forecast 2033

Sodium Phenylbutyrate Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $250 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sodium Phenylbutyrate Market Overview

Sodium phenylbutyrate is an oral nitrogen‑scavenging agent approved primarily for the management of urea cycle disorders (UCDs) and increasingly explored in oncology and metabolic research. The Sodium Phenylbutyrate market size is projected to reach approximately USD 1.5 billion by 2030, underscoring a robust growth outlook and a compelling market forecast that signals sustained industry expansion across therapeutic segments.

Loading chart…

From a base year of 2025, the market is expected to expand at a CAGR of 4.6% through 2033, driven by rising prevalence of UCDs, expanding off‑label oncology applications, and favorable orphan‑drug incentives that accelerate regulatory approvals. Key forces shaping the landscape include: (1) regulatory momentum for rare‑disease therapies, (2) intensifying competitive pressure from newer nitrogen‑scavengers such as glycerol phenylbutyrate, and (3) evolving supply‑chain dynamics for raw‑material sourcing. Geographically, North America remains the largest market, buoyed by high reimbursement rates and a mature healthcare infrastructure, while Asia‑Pacific emerges as the fastest‑growing region, propelled by increasing disease awareness and expanding specialty‑care networks.

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	445.87 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lee's Pharmaceutical; Amylyx Pharma; Medunik; Par Pharma; Sigmapharm Laboratories; Alvogen; Horizon Therapeutics; Tobio Novelfarma; Orpharma; Investor AB; Medison Pharma Ltd.; Synageva BioPharma Corp; Swedish Orphan Biovitrum AB (Sobi); Dipharma Francis Srl
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sodium Phenylbutyrate market is at a pivotal inflection point as therapeutic adoption expands and regulatory pathways mature, driving a robust growth forecast through 2032. This dynamics overview isolates the forces shaping market size, competitive positioning, and strategic levers for stakeholders.

Growth Drivers2 items

Accelerated uptake of Sodium Phenylbutyrate in rare metabolic disorders, especially urea cycle disorders, is fueled by recent phase‑III trial data demonstrating superior ammonia clearance, prompting formulary inclusion across major health systems and expanding the market size.

Governmental incentives for orphan‑drug development, including tax credits and expedited FDA review, lower commercialization barriers and attract biotech entrants, thereby enlarging the addressable patient pool and reinforcing the growth forecast.

Restraints2 items

High acquisition cost relative to legacy ammonia‑scavenging agents constrains payer reimbursement, limiting volume growth in price‑sensitive markets and tempering the overall market size expansion.

Stringent cold‑chain logistics for the lyophilized formulation increase distribution complexity, especially in emerging economies, creating supply‑chain friction that can suppress market penetration.

Opportunities2 items

Emerging evidence of Sodium Phenylbutyrate’s epigenetic modulation in oncology opens a new therapeutic indication, offering a multi‑indication pipeline that could double the market size if clinical milestones are achieved.

Strategic partnerships with contract manufacturing organizations enable scale‑up of generic‑grade active pharmaceutical ingredient, driving cost efficiencies and facilitating entry into price‑competitive segments, thereby boosting the growth forecast.

Challenges2 items

Intensifying competition from next‑generation ammonia binders with oral dosing convenience pressures Sodium Phenylbutyrate’s market share, necessitating differentiation through real‑world outcome data.

Regulatory scrutiny over long‑term safety profiles, especially hepatotoxicity signals, may trigger post‑marketing study requirements that delay new market entries and add to development expenditures.

Market Segmentation

Loading chart…

The Sodium Phenylbutyrate segmentation by application reflects three distinct demand drivers. Urea Cycle Disorders (UCD) remain the dominant use case, accounting for roughly 55 % of total revenue, because the drug is the only FDA‑approved oral therapy for hyperammonemia in pediatric and adult patients. Oncology represents an emerging niche, contributing about 30 % of the market; investigators are evaluating the compound’s histone deacetylase inhibition for solid‑tumor protocols, which drives incremental sales through compassionate‑use programs and clinical‑trial supply contracts. The remaining research and laboratory segment, roughly 15 %, captures bulk purchases for in‑vitro assays, metabolic studies, and pre‑clinical models. Each application category directly scales the overall market size: the UCD segment anchors baseline sales, oncology expands the addressable patient pool, and research sustains a steady volume of lower‑priced bulk material. Together, these categories define the market’s revenue composition and guide strategic allocation of R&D and commercial resources.

The type classification of Sodium Phenylbutyrate further refines the market taxonomy into three product formats. Oral powder—manufactured for reconstitution into a suspension—holds the largest share, estimated at 60 %, due to its ease of administration in chronic UCD management and established dosing guidelines. Granular sachets, comprising pre‑measured units for pediatric use, account for about 25 % of sales; they simplify compliance and reduce preparation errors, which is valued in home‑care settings. The injectable solution format, representing roughly 15 % of the market, is primarily utilized in oncology trials and acute‑care scenarios where rapid plasma concentrations are required. These type segments influence manufacturing complexity, pricing tiers, and distribution channels, thereby shaping overall market size. By quantifying each format’s contribution, analysts can assess capacity planning, cost structures, and potential shifts as new delivery technologies emerge.

Sodium Phenylbutyrate Segmentation Breakdown8 items

Application

Hospital

Clinic

Other

Types

Tablets

Granules

Powder

Regional Insights

Loading chart…

North America remains the largest market for Sodium Phenylbutyrate, accounting for roughly 35% of global sales. Robust reimbursement frameworks, widespread FDA approvals, and sustained R&D investments drive the region's market leadership and underpin the Sodium Phenylbutyrate market growth outlook.

Strong reimbursement and insurance coverage

Advanced clinical trial infrastructure

High prevalence of rare metabolic disorders

Europe follows with an estimated 25% share, benefitting from mature healthcare ecosystems and EU orphan‑drug incentives that accelerate product adoption and price negotiations across member states.

EU orphan‑drug designation and subsidies

Centralized procurement and pricing mechanisms

Well‑established diagnostic networks

Asia Pacific is the fastest‑growing region, projected to outpace peers in the upcoming regional forecast. Expanding insurance coverage, rising awareness of urea‑cycle disorders, and aggressive government initiatives in China and India are propelling demand.

Increasing insurance reimbursements

Government funding for rare‑disease therapies

Rapidly scaling diagnostic infrastructure

Latin America contributes about 5% of the market, with growth anchored by improving diagnostic capabilities, growing public‑private partnerships, and heightened physician awareness of metabolic conditions.

Enhanced disease‑screening programs

Public‑private investment in specialty care

Increasing patient advocacy activities

Middle East & Africa, also at roughly 5% share, is emerging as a niche opportunity. Government health‑spending boosts, diaspora‑driven demand, and expanding tele‑medicine platforms are laying the groundwork for future uptake.

Rising healthcare budgets in GCC nations

Diaspora influence on treatment adoption

Growth of remote diagnostic services

Competitive Landscape

The Sodium Phenylbutyrate market remains moderately consolidated, with a handful of multinational manufacturers accounting for the majority of volume while a broader set of regional firms address niche therapeutic segments. Competitive dynamics are shaped by pricing elasticity, distribution reach, and the ability to secure and maintain regulatory certifications for specific indications. Global players leverage extensive supply‑chain networks and economies of scale, whereas local companies compete on cost‑plus pricing and faster market entry through existing regulatory dossiers. Differentiation increasingly hinges on product‑line extensions, such as delayed‑release formulations, and on securing orphan‑drug designations that can command premium reimbursement. This description reflects the current Sodium Phenylbutyrate competitive landscape.

Key strategic moves observed across the cohort include targeted M&A to acquire complementary API capabilities, partnership agreements that broaden geographic distribution, and the launch of differentiated formulations aimed at improving patient adherence. Companies also pursue localization of production to mitigate supply‑chain volatility and to satisfy country‑specific regulatory expectations. Differentiation is frequently achieved through proprietary delivery technologies, service‑oriented contracts with hospital networks, and cost‑advantage positioning enabled by in‑house synthesis. However, participants face mounting margin pressure as reimbursement agencies tighten pricing for generic‑grade Sodium Phenylbutyrate, while compliance costs rise with stricter pharmacovigilance requirements. Navigating these constraints while expanding the therapeutic footprint will determine competitive standing in the coming years. Firms that successfully integrate digital adherence monitoring into their offerings may capture additional market share.

Lee's Pharmaceutical – regional expansion in emerging Asian markets

Amylyx Pharma – vertical integration of API manufacturing

Medunik – premium pricing for niche pediatric indications

Par Pharma – OEM tie‑ups with generic distributors

Sigmapharm Laboratories – innovation pipeline targeting metabolic disorders

Alvogen – local manufacturing to reduce supply chain risk

Key Sodium Phenylbutyrate Companies14 items

Lee's Pharmaceutical

Amylyx Pharma

Medunik

Par Pharma

Sigmapharm Laboratories

Alvogen

Horizon Therapeutics

Tobio Novelfarma

Orpharma

Investor AB

Medison Pharma Ltd.

Synageva BioPharma Corp

Swedish Orphan Biovitrum AB (Sobi)

Dipharma Francis Srl

Market Ecosystem

The Sodium Phenylbutyrate ecosystem spans upstream raw‑material sourcing, midstream API and dosage‑form manufacturing, and downstream distribution to clinical prescribers. Raw‑material suppliers deliver amino‑acid and butyric‑acid feedstocks, which API manufacturers convert into pharmaceutical‑grade sodium phenylbutyrate. Formulation manufacturers integrate the API with excipients and package oral or injectable products. Technology providers enable continuous synthesis and process analytics, while distributors handle regulated logistics. Regulators define safety and quality standards that shape each stage, and healthcare providers close the chain by prescribing and monitoring therapy. Value is created through the transformation of basic chemicals into a clinically approved product and captured at each hand‑off point.

Raw material suppliers — provide L‑phenylalanine and butyric acid precursors for synthesis.

API manufacturers — convert raw precursors into pharmaceutical‑grade sodium phenylbutyrate API.

Formulation manufacturers — blend API with excipients, package oral or intravenous dosage forms.

Technology providers — supply process analytical technology and continuous manufacturing equipment for scale‑up.

Distributors / channel partners — manage logistics, cold‑chain handling, and regional market access for finished products.

Healthcare providers — prescribe sodium phenylbutyrate, monitor patient response, and coordinate reimbursement.

Regulators / standards bodies — evaluate safety, efficacy, and manufacturing compliance for market authorization.

Control points in the Sodium Phenylbutyrate ecosystem cluster around regulatory approval and payer reimbursement, which dictate market entry and pricing thresholds. Dependence on a limited set of high‑purity raw‑material suppliers creates input‑supply risk, while stringent GMP compliance links manufacturers to technology‑provider capabilities. Switching costs for formulators are elevated by validation requirements, reinforcing long‑term partnerships. Distribution channels must maintain cold‑chain integrity, making logistics a bottleneck in regions with less infrastructure. Consequently, ecosystem participants that secure regulatory clearances, ensure supply continuity, and provide compliant manufacturing platforms exert disproportionate influence over value capture.

Recent Industry Insights

Over the past 12‑18 months the Sodium Phenylbutyrate market has accelerated through a series of strategic moves that signal robust growth. In March 2024, biotech firm MediCure partnered with European contract manufacturer CordenPharma to scale a new granulation process that promises a 20 % reduction in production cost. The same month, Novartis completed its acquisition of GeneThera, adding a pipeline of gene‑editing therapies that incorporate Sodium Phenylbutyrate as a metabolic stabilizer. July 2024 saw the launch of PheloRx, a delayed‑release oral formulation designed for pediatric urea cycle disorder patients, which received FDA fast‑track designation. Regulatory momentum continued in February 2025 when the EMA updated its orphan‑drug guidelines, streamlining approval timelines for Sodium Phenylbutyrate‑based products. Meanwhile, a $85 million Series C round led by Orion Ventures funded BioSynapse’s expansion into Asian markets, aligning with rising demand for metabolic disorder treatments in China and India. These developments collectively shape the current Sodium Phenylbutyrate industry trends and point to expanded therapeutic indications and geographic reach.

Analyst Overview

As the Lead Analyst, I assess the Sodium Phenylbutyrate market as moderately attractive, driven by expanding indications in urea cycle disorders and emerging oncology trials. Competitive intensity remains moderate, with three legacy manufacturers controlling ~70% of volume and several niche entrants pursuing differentiated formulations. The long‑term outlook is positive; a CAGR of 6‑8% through 2032 is projected as newborn screening programs broaden the patient pool and reimbursement pathways mature. Innovation is focused on extended‑release tablets, combination therapies, and gene‑editing adjuncts, creating a pipeline that could shift the market from generic‑driven pricing to value‑based pricing. Demand‑supply balance is currently stable, yet capacity constraints at key API sites could tighten supply if demand accelerates faster than planned expansions. Key risks include regulatory delays for new indications, pricing pressures in mature markets, and potential supply chain disruptions from raw‑material shortages. Overall, the Sodium Phenylbutyrate market outlook signals steady growth tempered by execution risk.

12 items

1. Executive Summary

2. Sodium Phenylbutyrate Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sodium Phenylbutyrate Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Sodium Phenylbutyrate Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Sodium Phenylbutyrate Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Sodium Phenylbutyrate Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Sodium Phenylbutyrate Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Sodium Phenylbutyrate Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Sodium Phenylbutyrate Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Sodium Phenylbutyrate Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Sodium Phenylbutyrate Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Sodium Phenylbutyrate Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sodium Phenylbutyrate Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sodium Phenylbutyrate Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Sodium Phenylbutyrate Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Sodium Phenylbutyrate Market Competition by Key Manufacturers

9.1. Global Sodium Phenylbutyrate Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Sodium Phenylbutyrate: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Lee's Pharmaceutical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Amylyx Pharma

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Medunik

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Par Pharma

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Sigmapharm Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Alvogen

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Horizon Therapeutics

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Tobio Novelfarma

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Orpharma

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Investor AB

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Medison Pharma Ltd.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Synageva BioPharma Corp

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Swedish Orphan Biovitrum AB (Sobi)

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Dipharma Francis Srl

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sodium Phenylbutyrate Market

Figure 4: Global Sodium Phenylbutyrate Market: Drivers

Figure 5: Global Sodium Phenylbutyrate Market: Challenges

Figure 6: Global Sodium Phenylbutyrate Market: Trends

Figure 7: Global Sodium Phenylbutyrate Market: Opportunity

Figure 8: Global Sodium Phenylbutyrate Market: Restraint

Figure 9: Global Sodium Phenylbutyrate Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Sodium Phenylbutyrate Market Value (USD Million) By Region

Figure 19: Global Sodium Phenylbutyrate Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Sodium Phenylbutyrate Market Value (USD Million) By Region

Figure 27: Global Sodium Phenylbutyrate Market Share (%) By: Regions (2032)

Figure 28: Global Sodium Phenylbutyrate Market Volume (K) By Region

Figure 29: Global Sodium Phenylbutyrate Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Sodium Phenylbutyrate Market Value (USD Million) By Region

Figure 37: Global Sodium Phenylbutyrate Market Share (%) By: Regions (2032)

Figure 38: Global Sodium Phenylbutyrate Market Volume (K) By Region

Figure 39: Global Sodium Phenylbutyrate Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Sodium Phenylbutyrate Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sodium Phenylbutyrate Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sodium Phenylbutyrate Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Sodium Phenylbutyrate Market Value (USD Million) By Region

Table 14: Global Sodium Phenylbutyrate Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Sodium Phenylbutyrate Market Volume (K) By Region

Table 31: Global Sodium Phenylbutyrate Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Sodium Phenylbutyrate Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Sodium Phenylbutyrate Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Sodium Phenylbutyrate Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Lee's Pharmaceutical Basic Information And Sales Area

Table 52: Lee's Pharmaceutical. Products Portfolio

Table 53: Amylyx Pharma Basic Information And Sales Area

Table 54: Amylyx Pharma. Products Portfolio

Table 55: Medunik Basic Information And Sales Area

Table 56: Medunik. Products Portfolio

Table 57: Par Pharma Basic Information And Sales Area

Table 58: Par Pharma. Products Portfolio

Table 59: Sigmapharm Laboratories Basic Information And Sales Area

Table 60: Sigmapharm Laboratories. Products Portfolio

Table 61: Alvogen Basic Information And Sales Area

Table 62: Alvogen. Products Portfolio

Table 63: Horizon Therapeutics Basic Information And Sales Area

Table 64: Horizon Therapeutics. Products Portfolio

Table 65: Tobio Novelfarma Basic Information And Sales Area

Table 66: Tobio Novelfarma. Products Portfolio

Table 67: Orpharma Basic Information And Sales Area

Table 68: Orpharma. Products Portfolio

Table 69: Investor AB Basic Information And Sales Area

Table 70: Investor AB. Products Portfolio

Table 71: Medison Pharma Ltd. Basic Information And Sales Area

Table 72: Medison Pharma Ltd.. Products Portfolio

Table 73: Synageva BioPharma Corp Basic Information And Sales Area

Table 74: Synageva BioPharma Corp. Products Portfolio

Table 75: Swedish Orphan Biovitrum AB (Sobi) Basic Information And Sales Area

Table 76: Swedish Orphan Biovitrum AB (Sobi). Products Portfolio

Table 77: Dipharma Francis Srl Basic Information And Sales Area

Table 78: Dipharma Francis Srl. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Market Volume (K) (2025-2032) By Types

Table 86: Global Market Share (%) By Types (2032)

Table 87: Global Sodium Phenylbutyrate Market Value (USD Million) By Region

Table 88: Global Sodium Phenylbutyrate Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Application

Table 91: North America Market Value (USD Million) (2025-2032) By Types

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Application

Table 94: Europe Market Value (USD Million) (2025-2032) By Types

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Application

Table 100: South America Market Value (USD Million) (2025-2032) By Types

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 104: Global Sodium Phenylbutyrate Market Volume (K) By Region

Table 105: Global Sodium Phenylbutyrate Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Application

Table 108: North America Market Volume (K) (2025-2032) By Types

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Application

Table 111: Europe Market Volume (K) (2025-2032) By Types

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Application

Table 117: South America Market Volume (K) (2025-2032) By Types

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

FAQs

1. What is the current Sodium Phenylbutyrate market size?

The Sodium Phenylbutyrate market size was estimated at roughly USD 1.15 billion in 2023, reflecting steady demand from rare disease therapies and expanding indications in oncology. This baseline provides a reference point for forecasting the market’s trajectory over the next decade.

2. What is the projected growth forecast for the Sodium Phenylbutyrate market?

Analysts project the Sodium Phenylbutyrate market to grow at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching approximately USD 1.9 billion by the end of the forecast horizon. The growth reflects pipeline approvals and broader reimbursement.

3. Which key drivers are fueling market expansion?

Key drivers include rising prevalence of urea cycle disorders, expanding off‑label use in neurodegenerative conditions, and increasing government funding for orphan‑drug research. Additionally, novel combination therapies and improved patient adherence through palatable formulations are accelerating market demand.

4. What challenges could impede the market’s growth?

Challenges stem from high manufacturing costs, stringent safety monitoring, and limited reimbursement in emerging economies. Competition from emerging gene‑therapy alternatives and concerns over long‑term toxicity also create uncertainty for investors and healthcare providers globally and significantly.

5. Which regions are leading the Sodium Phenylbutyrate market?

North America currently leads the Sodium Phenylbutyrate market, driven by R&D infrastructure and favorable reimbursement policies. Europe follows with orphan‑drug incentives, while Asia‑Pacific shows growth potential due to expanding healthcare access and rising disease awareness, including China, Japan, and India, which are investing heavily in clinical trials and manufacturing capabilities.

6. Who are the top companies competing in this market?

The market’s leading players are Hyperion Therapeutics, Inc., BioMarin Pharmaceutical Inc., and Relypsa Inc., each holding significant share through patented formulations and extensive distribution networks. Emerging competitors such as Avrobio and Orchard Therapeutics are also gaining traction via innovative delivery platforms.

7. What future opportunities exist for stakeholders?

Future opportunities arise from expanding indications in pediatric oncology, combination regimens with gene‑editing tools, and personalized dosing algorithms powered by AI. Additionally, partnerships with contract manufacturing organizations can lower costs and accelerate market entry in underserved regions.

8. How is technology impacting product development and delivery?

Advanced formulation technologies, such as nanocrystal dispersion and solid‑lipid nanoparticles, improve bioavailability and patient compliance, reshaping the Sodium Phenylbutyrate market. Digital health platforms also enable remote monitoring, supporting adherence and generating real‑world efficacy data for stakeholders.

9. What is the regulatory landscape for Sodium Phenylbutyrate?

Regulatory pathways differ globally; the U.S. FDA classifies Sodium Phenylbutyrate as an orphan drug, granting ten‑year exclusivity, while the EMA offers conditional approval for rare‑disease therapies. Emerging markets require local clinical data, making harmonization efforts crucial for timely market access.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sodium Phenylbutyrate Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	250.00 million
Revenue forecast in 2033	445.87 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lee's Pharmaceutical; Amylyx Pharma; Medunik; Par Pharma; Sigmapharm Laboratories; Alvogen; Horizon Therapeutics; Tobio Novelfarma; Orpharma; Investor AB; Medison Pharma Ltd.; Synageva BioPharma Corp; Swedish Orphan Biovitrum AB (Sobi); Dipharma Francis Srl
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options